Background: Acute Lymphoblastic Leukemia (ALL) is a malignant disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. Further improvement of outcome in childhood acute lymphoblastic leukemia could be achieved by identifying additional high-risk patients who may benefit from intensified treatment. CD45 cell surface antigen is a transmembrane protein with tyrosine phosphatase activity, expressed by all nucleated cells of hematopoietic origin, except erythrocytes and platelets.
Introduction
ACUTE Lymphoblastic Leukemia (ALL): ALL is a malignant clonal disorder of bone marrow lymphopoietic precursor cells with progressive medullary and extramedullary accumulation of lymphoblast that decreases the potential for differentiation and maturation [1] . ALL is the most common childhood malignancy, constituting about one third of childhood cancer [2] .
With improvements in diagnosis and treatment, overall cure rates for children with ALL have reached 90%. The use of risk-adapted treatment protocols has improved cure rates while limiting the toxicity of therapy [3] .
Although treatment of acute lymphoblastic leukemia has improved continuously over the last decades, first-line therapy still fails in approximately 20% of cases and children suffer from disease recurrence [4] .
Further reduction of relapse in childhood ALL could be achieved by identifying additional highrisk patient who may benefit from treatment intensification [5] .
CD45 Antigen:
The leukocyte common antigen or CD45 is found on all hematopoietic cells except erythrocytes and platelets and is absent from non hematopoietic tissues. It belongs to a family of cell surface glycoproteins with a heavily glycosylated extracellular domain, a transmembrane segment, and a large cytoplasmic domain that contains tyrosine phosphatase activity [6] .
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Since CD45 is exclusively found on hematopoietic cells, apart from erythrocytes and platelets, its greatest diagnostic value is in distinguishing the hematopoietic from the nonhematopoietic tissue [7] .
CD45 is a part of the immunophenotyping marker panels for the diagnosis of acute leukemias. It is used to define the blast population, on which the expression of differentiation antigens is to be focused [8] .
Routinely, CD45 expression was reported in terms of percentage of positive cells. This approach does not, however, allow for quantification of the brightness of expression. In fact, using this approach we were previously unable to demonstrate an association between CD45 expression and prognosis because blast cells are generally CD45 positive and the number of true negative CD45 cases in ALL is very rare, or may not exist at all [9] .
By contrast, analysis of CD45 antigen by demonstration of its density on blast cells revealed its potential prognostic significance [5] .
Patients and Methods
This study was done after approval from Ethical Committee of Research Center of Tanta University Hospital and written consent from parents of included children in this research and was carried out at Hematology and Oncology Unit, Pediatric Department, Tanta University between April-2017 and April 2018 on 25 patient of acute lymphoblastic leukaemia-including precursor B-cell and T-cell phenotype-who received risk-oriented therapy depend on the stratification criteria which divide them into low risk, standard risk, and high risk patients according to total XV protocol.
Patient's age ranged from 2-7 years, with mean ± SD 6.88 ±4.62. They were 17 males (68%) and 8 females (32%).
All patients was subjected to detailed history, thorough clinical examination, radiological investigation-including abdominopelvic U/S, chest Xray, echocardiography and testicular U/S in malesand laboratory investigations include the following: CBC, ESR, LDH, liver and renal function test, Serum uric acid, Na, K, Ca, Ph serum level, coagulation profil, lumber puncture for CSF examination and bone marrow aspiration and examination by the following: (Leishman stained smears to detect the percentage of blast cells, cytochemical analysis, Immunopheno-typing of blast cells by flowcytometry, cytogenetic study including DNA index and t(9, 22) and MRD assessment at day 15 and at end of induction therapy).
Diagnosis of acute lymphoblastic leukemia was based on morphological, cytochemical and immunophenotypic characteristics of leukemic blasts.
Flow cytometric measurement and quantification of CD45 surface expression:
CD45 expression was routinely assessed at diagnostic immunophenotyping, samples were taken prior to the initiation of treatment, they were analyzed and reported according to the guidelines proposed by the European Group for the Immunological Characterization of Leukemias (EGIL). Accordingly, antigen expression was quantified in terms of percentage of positive cells as compared to an antigen-negative subpopulation.
In the study presented here, we re-analyzed the "raw" flow cytometric data and quantified CD45 expression in order to provide a full-scale estimation of CD45 expression. To control for technical variation, we normalized the measured expression values by use of normal mature B-and T-lymphocytes within the same sample, which are known to express high levels of CD45 stably. The resulting expression values are described as relative ratios of mean fluorescence intensity of CD45 in leukemic versus normal cells in percentages.
The cutoff point was set on ≥90% to distinguish CD45-low from CD45-high groups.
All patients were treated according to total XV protocol which consists of remission induction, consolidation and continuation phases [10] . 4, 6, 9, 11, 13) , cyclophosphamide 1000mg/m 2 (d22), cytarabine 75mg/m 2 (d23-d26 and d30-d33), Mercaptopurine 60mg/m 2 /day (d22-d35), triple intrathecal (d1, 15). Upon hematopoietic recovery (between day 39 and 42), MRD was assessed and consolidation therapy began.
Remission induction: Consists of prednisone
Patients were followed-up to assess their response to treatment and for incidence of relapse.
Definition of complete remission and relapse:
Complete Remission (CR) is defined as a cellularity of more than 20% with fewer than 5% blasts in bone marrow after induction chemotherapy. 19 relapse is defined by the appearance of one of the following: (1) More than 50% lymphoblasts in a 
Results
In (Table 1) : There is statistical significant difference between age groups and CD45 expression. In low CD45 expression group, age of patient range from 2-8 years (favorable age group) years with mean ± SD (4.25 ±2.04). In high CD45 expression group, age of patient ranges from 3-17 years with mean ± SD (8.63 ±5.07).
No statically significance between WBCs count groups at initial diagnosis and CD45 expression ( Table 2 ). No statistical significance was found between CD45 expression and DNA index ( Table 4 ).
In (Table 5 ) 100% and 93.3% of patients with low CD45 and high CD45 expression respectively were -ve for BCR/ABL fusion gene. 6.7% of patient with high CD45 were +ve for BCR/ABL fusion gene, with no statistical significance. In (Table 6) : At end of induction MRD was not detected (<0.01%) in 90% and 60% of patients in low CD45 and high CD45 groups respectively MRD was positive (≥0.01%) in 10% and 40% of patients in low and high CD45 groups respectively, with no statistical significance. In Fig. (2) : 100% of patients with low CD45 expression could achieve Complete Remission (CR) early while only 66.7% of patients in the high group could do. With statistical significance, p-value=0.041 Fig. (2) . In Fig. (3) : In CD45-low group 80% of patients were of Low Risk (LR) and 20% were Standard Risk (SR). In CD45-high group 66.7% of patients were standard risk, 20% low risk and 13.3% high risk. With statistical significance (p-value=0.011). deaths with CD45 expression Figs. (6,7) . 
Discussion
Regarding the relation between age and CD45 expression, 100% of patients of CD45-low group were in the favorable age group versus 60% of patients of CD45-high group. This agrees with [5] . who found that among the low CD45 patient 56% had a favorable age versus 17% in the high CD45 group. But [9,12-14] failed to find any relation between age and CD45 expression.
WBCs count at diagnosis did not correlate with the level of CD 45 expression, this in agreement with [12-15] who report an adult ALL case with bright CD45 expression with normal leucocytic count. But in disagreement with [5] . Who found that in B-ALL cases patients who presented with TLC more than 50,000 were 9% in CD45-low group versus 28.8% in CD45-high group, and in T-ALL cases they were 49.5% and 82.8% in low and high-CD45 groups respectively.
Regarding leukemic phenotype, there was no significant correlation with CD45 level of expression in contrast to [5, 12, 16, 17] all found that the expression of antigen was more intense in the T-ALL cases than in B-precursor ALL cases.
DNA index ranged from 1 to 1.32 in the low group while in the high group all patients were of normal diploid number with DNA index 1 in all cases. But, no stastical significance was found between DNA index and CD45 expression. This in agreement with [13, 14] , and in disagreement with [9] who found that cases lacking the antigen were more likely to have a DNA index greater than 1.15. [5] . Found that DNA index was significantly related to CD45 expression in B-cell ALL where 22.4% of patients in CD45-low group had a DNA index >_ 1.16 versus 5.3% in CD45-high group, but no significant relation was found in T-cell ALL. However, [18] reported a case of bright CD45 expression but with hyperdiploid number chromosomes. BCR/ABL fusion gene was found in only one case that had high CD45 expression, but there was no significant difference between CD 45-low and CD45-high groups regarding BCR/ABL fusion gene presence or absence. This in agreement with [9,12,13] , but in disagreement with [5] , as BCR/ABL fusion gene was positive in 11 cases (4.5%) of CD45-high group. [15, 18] both found negative BCR/ABL fusion gene in spite of high CD45 intensity.
In our result 100% of patients of low CD45 expression could achieve complete remission early at day 15 of induction in contrast to the high group where only 66.7% of patient could do. This result in agreement with [5] . Who found that in Bprecursor ALL with low antigen expression 95.3% were early treatment responders versus 89.5% in the high group.
In T-ALL cases, 63.8% of the low group were good responders versus 32.4% in the high group. [8, 9] also suggested an inverse relationship between quantitative CD45 expression and therapeutic outcome. But, [13] failed to find any relation between CD45 expression and treatment outcome. Also [18] reported that his case could achieve complete remission early in spite of high CD45 density.
Regarding MRD assessment at end of induction therapy, it was undetectable (<0.01%) in 90% of the low group versus 60% of the high group, but without statistical significant difference between the two groups. In contrast to [5] . Who found highly significant difference between CD45-low and CD45 high group regarding MRD level.
Patients were stratified into low, standard and high risk groups according to risk stratification criteria in TOTAL XV protocol. In CD45-low group, 80% of patients were of Low Risk (LR) and 20% were Standard Risk (SR) while in the CD45-high group 66.7% of patients were standard risk, 20% low risk and 13.3% High Risk (HR), so there was statistical significant correlation between risk stratification and antigen expression. This came in agreement with [5] . Where patients were stratified according to NCI stratification system, among cases of BCP ALL 73.2% of patient with CD45 low expression were stratified as standard risk and 26.8% were high risk in contrast to the high CD45 expression group that consisted of 50.2% standard risk and 49.8% high risk patients. T-ALL CD45-low group consisted of 21.9% and 78.1% standard and high risk respectively while in CD45-high group there were 2.9% and 97.1% standard and high risk respectively. Event-free survival was calculated from the date of diagnosis to last follow-up or to the first event. Patients with high CD45 expression had a worse 2-year event-free survival probability (66.7%) compared to patients with low expression (80%). This agrees with [5] . Who found that there was a worse 5-year event-free survival in high CD45 cases than the low (BCP-ALL: 72% in CD45-high versus 86%in CD45-low; T-ALL: 60% versus 78%). Also agrees with [12] who found that in the high-risk patients, the two groups showed a striking difference in their EFS rates: The 3-year EFS rates were 88.7% in CD45-low versus 34% in CD45-high. [7] also found that there was better cumulative survival in patients with CD45 lower intensity.
This effect was mainly related to a higher incidence of relapse in CD45-high group (46.6% versus 0% in the low group). This came in agreement with [5] who found that incidence of relapse had high significant relation to CD45 expression (BCP-ALL: 22% in CD45-high versus 11% CD45-low group, T-ALL: 31% versus 11%) and with [15] whose case with bright CD45 developed an early relapse.
